BRPI0408417A - métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição - Google Patents

métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição

Info

Publication number
BRPI0408417A
BRPI0408417A BRPI0408417-9A BRPI0408417A BRPI0408417A BR PI0408417 A BRPI0408417 A BR PI0408417A BR PI0408417 A BRPI0408417 A BR PI0408417A BR PI0408417 A BRPI0408417 A BR PI0408417A
Authority
BR
Brazil
Prior art keywords
serine protease
gla residue
containing gla
purifying
residue
Prior art date
Application number
BRPI0408417-9A
Other languages
English (en)
Inventor
Janus Krarup
Egon Persson
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BRPI0408417A publication Critical patent/BRPI0408417A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"MéTODOS PARA A PRODUçãO DE UM RESìDUO DE GLA PURIFICADO CONTENDO SERINA PROTEASE, PARA A PURIFICAçãO DE UM RESìDUO DE GLA CONTENDO SERINA PROTEASE E PARA ESTABILIZAçãO DE UM RESìDUO DE GLA CONTENDO SERINA PROTEASE, E, COMPOSIçãO". A presente invenção diz respeito a um processo para a purificação de uma protease.
BRPI0408417-9A 2003-03-18 2004-03-18 métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição BRPI0408417A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300413 2003-03-18
US45780903P 2003-03-26 2003-03-26
PCT/DK2004/000183 WO2004083421A1 (en) 2003-03-18 2004-03-18 Method for the production of gla-residue containing serine proteases

Publications (1)

Publication Number Publication Date
BRPI0408417A true BRPI0408417A (pt) 2006-03-21

Family

ID=33031170

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408417-9A BRPI0408417A (pt) 2003-03-18 2004-03-18 métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição

Country Status (10)

Country Link
EP (2) EP1611236A1 (pt)
JP (1) JP4885707B2 (pt)
KR (1) KR101204712B1 (pt)
CN (4) CN101818138A (pt)
AU (1) AU2004221758B2 (pt)
BR (1) BRPI0408417A (pt)
CA (1) CA2519020A1 (pt)
MX (1) MXPA05009770A (pt)
RU (1) RU2364626C2 (pt)
WO (1) WO2004083421A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2292682T3 (es) 1998-05-06 2008-03-16 Genentech, Inc. Purificacion de anticuerpos mediante cromatografia de intercambio ionico.
US7985569B2 (en) * 2003-11-19 2011-07-26 Danisco Us Inc. Cellulomonas 69B4 serine protease variants
AU2012213951B2 (en) * 2005-04-28 2014-10-16 Novo Nordisk Health Care Ag A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit
BRPI0608170A2 (pt) * 2005-04-28 2010-11-09 Novo Nordisk Healthcare Ag recipiente fechado contendo uma composição de um polipeptìdeo do fator vii ativado, processo para a preparação de um recipiente fechado contendo um polipeptìdeo do fator vii ativado, kit, e, método para a preparação de uma composição farmacêutica
KR20080039969A (ko) * 2005-08-31 2008-05-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Ｇｌａ 도메인을 결합하는 인간 ｆｖｉｉ 단일클론의 항체및 이것의 사용
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
CN102239175A (zh) * 2008-12-02 2011-11-09 诺沃-诺迪斯克保健股份有限公司 多肽的纯化
EP2526115B1 (en) 2010-01-18 2018-08-01 Novo Nordisk Health Care AG Purification of blood coagulation factors
SG10201913700SA (en) * 2010-07-09 2020-03-30 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
KR102001662B1 (ko) 2011-06-17 2019-10-01 학교법인 히가시-니뽄-가쿠엔 루프스 안티코아귤란트 검출용 혈액 응고시간의 측정방법
CN103539852B (zh) * 2012-07-12 2015-08-12 上海泰龙生物医药科技有限公司 一种从细胞培养液中分离纯化重组人凝血八因子的方法
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN109876136B (zh) * 2019-02-21 2019-12-31 国药集团成都信立邦生物制药有限公司 一种醋酸奥曲肽冻干粉针剂及其制备方法
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8615942D0 (en) 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
NZ221259A (en) 1986-07-31 1990-05-28 Calgene Inc Seed specific transcriptional regulation
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
GB8826446D0 (en) 1988-11-11 1988-12-14 Agricultural & Food Res Peptide production
JP2824430B2 (ja) * 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
US5073964A (en) 1989-08-04 1991-12-17 Aware, Inc. Signal processing device and method
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
CA2074839C (en) 1990-01-29 2000-11-14 Kathleen L. Berkner Modified factor vii anticoagulant proteins
AU1228592A (en) 1991-01-11 1992-08-17 American Red Cross Expression of active human protein c in mammary tissue of transgenic animals
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
FR2684999A1 (fr) 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
DK38293D0 (da) * 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) * 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
DE19937219A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
AU6558400A (en) * 1999-08-17 2001-03-13 Novo Nordisk A/S Stabilisation of freeze-dried cake
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
PL204285B1 (pl) 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
EP1282693B1 (en) 2000-05-03 2010-10-20 Novo Nordisk Health Care AG Human coagulation factor vii variants
IL154520A0 (en) * 2000-09-13 2003-09-17 Novo Nordisk As Human coagulation factor vii variants
AU9165201A (en) * 2000-10-02 2002-04-15 Novo Nordisk As Factor vii glycoforms
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
AU2003223925A1 (en) * 2002-05-03 2003-11-17 Novo Nordisk A/S Stabilised solid compositions of modified factor vii

Also Published As

Publication number Publication date
RU2364626C2 (ru) 2009-08-20
CN1761747A (zh) 2006-04-19
CN101818138A (zh) 2010-09-01
RU2005132170A (ru) 2007-06-20
AU2004221758B2 (en) 2010-07-22
EP3103869A1 (en) 2016-12-14
EP1611236A1 (en) 2006-01-04
JP2006520200A (ja) 2006-09-07
CA2519020A1 (en) 2004-09-30
AU2004221758A1 (en) 2004-09-30
CN101818137A (zh) 2010-09-01
KR101204712B1 (ko) 2012-11-27
WO2004083421A1 (en) 2004-09-30
JP4885707B2 (ja) 2012-02-29
KR20050110016A (ko) 2005-11-22
CN1780637A (zh) 2006-05-31
MXPA05009770A (es) 2005-11-17

Similar Documents

Publication Publication Date Title
BRPI0408417A (pt) métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição
PL367527A1 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
DE60201480D1 (de) Verfahren zur Herstellung von hochreinem Xylylendiamin
ATE452870T1 (de) (meth)acrylsaeurekristall und verfahren zur herstellung und aufreinigung von waessriger (meth)acrylsaeure
ATE469189T1 (de) Schwach gefärbte natriumarme benzoxazinon-uv- absorber und verfahren zu ihrer herstellung
BR0308261A (pt) Métodos extrativos para puruficação de sucralose
MXPA05012362A (es) Yodopirazolilcarboxanilidas.
UA95083C2 (ru) Азеотропная или близкая к азеотропной композиции, которые содержат 1,1,1,2,3-пентафторопропен и фтороводород, способы отделения и получения 1,1,1,2,3-пентафторопропена
EP1411027A4 (en) PROCESS FOR CLEANING CHLORINE AND METHOD FOR PRODUCING 1,2-DICHLORETHANE
GB0216001D0 (en) Process and composition
DE60207031D1 (de) Verfahren zur herstellung von octafluorocyclobutan
BRPI0417992A (pt) método para purificar fsh
DE60205083D1 (de) Verfahren zur herstellung von octafluoropropan
BRPI0508973A (pt) método para a purificação de um metal fundido
TW200508179A (en) Purification of dimethylacetamide (DMAc)
DE60114048D1 (de) Verfahren zur aufreinigung von maltose
AU2003258335A1 (en) A method for the purification of lansoprazole
DE60138712D1 (de) O-butanen
BRPI0411634A (pt) método e dispositivo para purificação de ar e água
IT1319679B1 (it) Processo di purificazione di fosfatidilserina.
ECSP024388A (es) Inhibidores de proteasas
MXPA03001272A (es) Procedimiento para la preparacion de dinapsolina.
BRPI0411652A (pt) processo para a preparação de derivados de espirobenzoazepina substituìdos não-peptìdicos
DE60200535D1 (de) Verfahren zur Herstellung von hoch reinem Pemirolast
MY133586A (en) Novel phosphonic acid compounds as inhibitors of serine proteases

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]